YD Bio Limited Ordinary Shares cash flow to debt ratio of -97.53K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

YD Bio Limited Ordinary Shares's free cash flow has decreased 69.27% from $-4.75M last year to $-8.04M, signaling decreasing performance

YD Bio Limited Ordinary Shares's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

YD Bio Limited Ordinary Shares's debt has decreased relative to shareholder equity from 0.00 last year to 0.00 today, signaling strengthened financials

YD Bio Limited Ordinary Shares has a net cash position, so leverage is healthy.

YD Bio Limited Ordinary Shares earns at least as much interest as it pays. Interest obligations are fully covered.

YD Bio Limited Ordinary Shares's profit margin has increased (-100.00%) in the last year from -276.58% to 0.00%, signaling increasing performance

YD Bio Limited Ordinary Shares's short-term assets of $9.67M exceed its short-term liabilities of $1.64M

YD Bio Limited Ordinary Shares's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

YD Bio Limited Ordinary Shares's return on equity of 52.09%, is higher than 15.00%, indicating good performance

YD Bio Limited Ordinary Shares's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

YD Bio Limited Ordinary Shares has insufficient public price history to evaluate earnings stability.

YD Bio Limited Ordinary Shares has negative free cash flow, indicating the company is burning cash rather than generating it

YD Bio Limited Ordinary Shares has negative free cash flow, indicating cash burn

YD Bio Limited Ordinary Shares's yearly earnings has decreased 488.80% since last year from $-1.41M to $-8.31M, signaling decreasing performance

YD Bio Limited Ordinary Shares's yearly revenue has increased 16.94% since last year from $510.36K to $596.82K, signaling increasing performance

ROIC -6.12% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

YD Bio Limited Ordinary Shares has insufficient revenue history to calculate 3-year revenue CAGR.

YD Bio Limited Ordinary Shares has insufficient public price history to evaluate revenue consistency.

YD Bio Limited Ordinary Shares has insufficient public price history to evaluate ROE consistency.

YD Bio Limited Ordinary Shares has insufficient data to evaluate this check.

YD Bio Limited Ordinary Shares has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

YD Bio Limited Ordinary Shares is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

YD Bio Limited Ordinary Shares has negative or missing EBITDA, making EV/EBITDA ratio unreliable

YD Bio Limited Ordinary Shares has insufficient data to evaluate this check.

YD Bio Limited Ordinary Shares has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

YD Bio Limited Ordinary Shares has negative shareholder equity; price-to-book is not meaningful and the check fails

YD Bio Limited Ordinary Shares has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue